Uterine papillary serous carcinomas: the exigency for clinical trials
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference6 articles.
1. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma;Hendrickson;J Surg Pathol,1982
2. Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus: pathology review and analysis of prognostic variables;Hendrickson;Gynecol Oncol,1982
3. Slomovitz BM, Burke TW, Eifel PJ, . Uterine papillary serous carcinomas (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003;91:463–469
4. Huh WK, Powell M, Leath CA III, . Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003;91:470–475
5. Hematogeous dissemination in corpus cancer;Mariani;Gynecol Oncol,2001
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Many Faces of Serous Neoplasms and Related Lesions of the Female Pelvis: A Review;Advances in Anatomic Pathology;2022-02-18
2. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo;Gynecologic Oncology;2021-11
3. Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu;Gynecologic Oncology;2021-10
4. ONC206, an Imipridone Derivative, Induces Cell Death Through Activation of the Integrated Stress Response in Serous Endometrial Cancer In Vitro;Frontiers in Oncology;2020-10-20
5. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis;Clinical Cancer Research;2020-06-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3